CANNABIDIOL AS A NOVEL THERAPY FOR ALZHEIMER’S DISEASE
CANNABIDIOL

Palavras-chave

Cannabidiol; Alzheimer’s; Treatment; CBD.

Como Citar

Raquel Xavier Viana, T. . (2023). CANNABIDIOL AS A NOVEL THERAPY FOR ALZHEIMER’S DISEASE. Health and Society, 3(04), 182–200. https://doi.org/10.51249/hs.v3i04.1466

Resumo

Alzheimer’s disease (AD) is a progressive and incurable neurodegenerative condition that affects millions of people worldwide. The search for effective treatments for this disease has long been a priority in healthcare. In recent years, interest in the use of cannabidiol (CBD), one of the compounds found in the Cannabis sativa plant, has grown due to its potential therapeutic properties. A literature review was conducted covering searches in electronic databases, such as PubMed, SciELO and LILACS, with the aim of gathering as much information on the selected theme. Descriptors such as “Alzheimer”, “Cannabidiol”, “Treatment” and “CBD” were used, combined with the Boolean operator AND. The selection of articles considered the date of recent publication, limited to the last 10 years, as well as research related to the same theme and articles in Portuguese or foreign language (English). Duplicate articles, those that did not fit the proposed theme, as well as theses, monographs and dissertations were excluded. It was observed that CBD has characteristics often associated with Alzheimer’s therapy, such as anti-inflammatory, neuroprotective properties and mild adverse effects. The results indicated that the use of CBD in Alzheimer’s treatment shows promising potential. CBD was found to be especially beneficial for patients with neurodegenerative diseases. In conclusion, Cannabis is a viable substance given its promising therapeutic properties in the context of neuronal health, and its approach shows positive results in terms of recovery, symptomatologic improvement, and quality of life for patients affected by Alzheimer’s. Despite limitations and the need for further studies, results to date suggest that CBD may represent a promising option for symptomatic treatment and possibly even for modifying disease progression. However, it is critical to conduct larger-scale controlled clinical trials to confirm these findings and establish clear guidelines for its clinical use. These results may provide input for the development of future research and promising therapeutic strategies for Alzheimer’s disease.

https://doi.org/10.51249/hs.v3i04.1466
CANNABIDIOL

Referências

AHMED, A. I. et al. Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. Psychopharmacology (Berl), v. 232, n. 14, p. 2587-2595, jul. 2015. PMID: 25752889; PMCID: PMC4480847.

ASSOCIAÇÃO BRASILEIRA DE ALZHEIMER. Doença de Alzheimer. [Online]. Disponível em: http://abraz.org.br/web/. Acesso em: 13 maio 2023.

CALDAS, N. D. B.; BATISTA, F. L. Uso do canabidiol no tratamento de Alzheimer. Saúde Ciência Ação, v. 8, n. 1, p. 49-58, 2022.

CAMARGO FILHO, M. et al. Canabinoides como uma nova opção terapêutica nas doenças de Parkinson e de Alzheimer: uma revisão de literatura. Rev Bras Neurol, v. 55, n. 2, 2019. Disponível em: <https://doi.org/10.46979/rbn.v55i2.26911>. Acesso em: 18 maio 2023.

CAMPOS, A. C. et al. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res, v. 112, p. 119-127, out. 2016. PMID: 26845349.

CASSANO, T. et al. Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target. Front Neurosci, v. 11, p. 30, 2017.

CASSANO, T. et al. From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases. Front Pharmacol, v. 11, p. 124, 6 mar. 2020. PMID: 32210795; PMCID: PMC7069528.

CHAGAS, M. H. et al. Canabidiol pode melhorar comportamentos complexos relacionados ao sono associados ao distúrbio comportamental do sono de movimento rápido dos olhos em pacientes com doença de Parkinson: uma série de casos. J Clin Pharm Ther, v. 39, n. 5, p. 564-566, out. 2014. PMID: 24845114.

CHENG, D. et al. Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer’s disease transgenic mice. J Alzheimers Dis, v. 42, n. 4, p. 1383-1396, 2014. PMID: 25024347.

CHUNG, J. A.; CUMMINGS, J. L. Neurobehavioral and neuropsychiatric symptoms in Alzheimer’s disease: characteristics and treatment. Neurol Clin, v. 18, n. 4, p. 829-846, nov. 2000. PMID: 11072263.

CRIPPA, J. A. et al. Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age. Front Immunol, v. 9, p. 2009, 21 set. 2018. PMID: 30298064; PMCID: PMC6161644.

DHAGE, P. A. et al. Leveraging hallmark Alzheimer’s molecular targets using phytoconstituents: Current perspective and emerging trends. Biomedicine & Pharmacotherapy, v. 139, jan. 2021. PMID: 33383355.

DONG, H.; ZHANG, L.; LIU, W.; TIAN, Y. Label-Free Electrochemical Biosensor for Monitoring of Chloride Ion in an Animal Model of Alzheimer’s Disease. ACS Chem Neurosci., v. 8, n. 2, p. 339-346, 2017. PMID: 27992175.

ESPOSITO, G. et al. Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLoS One, v. 6, n. 12, p. e28668, 2011. PMID: 22163051; PMCID: PMC3230631.

FERNÁNDEZ-RUIZ, J.; MORO, M. A.; MARTÍNEZ-ORGADO, J. Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications. Neurotherapeutics, v. 12, n. 4, p. 793-806, out. 2015. PMID: 26260390; PMCID: PMC4604192.

GONTIJO, E. C. et al. Canabidiol e suas aplicações terapêuticas. Revista Eletrônica da Faculdade de Ceres, v. 5, n. 1, p. 37-48, 2016. Disponível em: http://periodicos.unievangelica.edu.br/index.php/refacer/article/view/3360/2360. Acesso em: 21 maio 2023.

GURGEL, H. L. C. et al. Uso terapêutico do canabidiol: a demanda judicial no estado de Pernambuco, Brasil. Saúde & Sociedade, v. 28, n. 3, p. 283-295, 2019. Disponível em: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0104-12902019000300283&lng=en&nrm=iso. Acesso em: 23 maio 2023.

ITAGAKI, S.; MCGEER, P. L.; AKIYAMA, H.; ZHU, S.; SELKOE, D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol, v. 24, n. 3, p. 173-182, out. 1989. PMID: 2808689.

KOZELA, E. et al. Modulation of astrocyte activity by cannabidiol, a nonpsychoactive cannabinoid. International Journal of Molecular Sciences, v. 18, n. 8, p. 1669-1689, ago. 2017. PMID: 28777350; PMCID: PMC5576607.

MAROON, J.; BOST, J. Review of the neurological benefits of phytocannabinoids. Surg Neurol Int, v. 9, p. 91, 26 abr. 2018. PMID: 29770251; PMCID: PMC5938896.

REIS, J.P. et al. Ação terapêutica da cannabis sativa em doenças neurodegenerativas. Brazilian Journal of Development, v. 8, n. 5, p. 40100-40112, 2022.

REIS, J.P.; FIGUEIREDO, N.N.; LIMA, R.P.; SANTANA, S.A. Ação terapêutica da cannabis sativa em doenças neurodegenerativas. Brazilian Journal of Development, v. 8, n. 5, p. 40100-40112, 2022.

ROCHA JUNIOR, A.M. et al. Uso do canabidiol como terapia alternativa para tratamento de epilepsia: revisão sistemática. Brazilian Journal of Development, v. 8, n. 5, p. 40580-40597, 2022.

RUSSO, E. B. Cannabis Therapeutics and the Future of Neurology. Front Integr Neurosci, v. 12, p. 1, 2018. Disponível em: <https://doi.org/10.3389/fnint.2018.00051>. Acesso em: 18 maio 2023.

SCHUBERT, D.; HARVEY, J.; POTTRATZ, S. T. Efficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimer’s Disease. Mol Neurobiol, v. 56, n. 11, p. 7719-7730, nov. 2019. PMID: 31089992.

SI, Z.; SUN, L.; WANG, X. Evidence and perspectives of cell senescence in neurodegenerative diseases. Biomed Pharmacother, v. 137, 2021.

SILVA, A.K.S.; VASCONCELOS, T.C.L. Uso medicinal da cannabis no tratamento da Doença de Alzheimer. Research, Society and Development, v. 11, n. 8, p. 178-148, 2022.

SILVA, A.L.M. et al. Abordagem terapêutica do Canabidiol sobre as Doenças Neurodegenerativas: avaliação dos efeitos na progressão dessas doenças e seus sintomas. Research, Society and Development, v. 11, n. 8, p. 564-585, 2022.

SILVA, S. F. P.; ARAÚJO, A. H. I. M.; MENDES, M. I. O. I. Asssitencia de Enfermagem ao paciente portador de Alzheimer: uma revisão de literatura. Rev JRG Estud Acad, v. 4, n. 8, p. 67–78, 2021.

SOUSA, I. G. D.; MARQUES, N. M. Descobertas sobre o uso de cannabis na doença de alzheimer: uma revisão da literatura. In: Congresso Internacional de Envelhecimento Humano, 6, 2019, Campina Grande. Anais eletrônicos... Campina Grande, 2019. Disponível em: https://editorarealize.com.br/revistas/cieh/trabalhos/TRABALHO_EV125_MD4_SA2_ID2756_27052019222514.pdf. Acesso em: 16 maio 2023.

SPEZZIA, S. O emprego da cannabis medicinal no enfrentamento de doenças. Revista Ciência Médica, v. 3, n. 5, p. 225-398, 2022.

Creative Commons License
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.

Copyright (c) 2023 Tereza Raquel Xavier Viana

Downloads

Não há dados estatísticos.

Métricas

Carregando Métricas ...